Perspective Therapeutics, Inc. — Investor Relations & Filings

Perspective Therapeutics, Inc. is a clinical-stage radiopharmaceutical company that pioneers advanced treatments for cancer. The company specializes in developing image-guided, targeted alpha-particle therapies (TATs). Its core technology utilizes the alpha-emitting isotope Lead-212 (Pb-212) conjugated to high-affinity, tumor-specific peptides to deliver potent radiation directly to cancer cells. This approach is designed to maximize efficacy against tumors while minimizing damage to surrounding healthy tissue. The company's theranostics platform uses the chemically matched isotope pair Pb-203/212, allowing physicians to visualize tumor targets to assist with patient selection and optimize treatment. Its clinical pipeline is focused on various cancers, including melanoma, neuroendocrine tumors, and other solid tumors.